Platelet Activation on Lung Function During Ex Vivo Lung Perfusion, Lung Transplantation, and the Role of Antiplatelet Therapy: A Narrative Review.

BACKGROUND

Ischemia/reperfusion injury after lung transplantation is a significant cause of morbidity. In the realm of ex vivo lung perfusion (EVLP), inflammation, edema formation, and reduced compliance have limited the durability of EVLP. Previous evidence has suggested that platelet activation and thrombosis may play a role in both conditions.

METHODS

A literature search of PubMed and Embase was conducted, including all articles describing all human or animal investigations of platelet activation or the use of antiplatelet agents in the settings of EVLP or lung transplantation. Articles published from database inception to July 15, 2024, were analyzed.

RESULTS

In total, 9 studies were included in the review. Studies on EVLP have found an association between platelet activation and adverse effects on lung function, whereas in lung transplantation, platelet activation appears to play a role in primary graft dysfunction. In both settings, the inhibition of platelets ameliorated these effects.

CONCLUSIONS

Platelet activation in EVLP and lung transplantation results in distal arterial thrombosis and has been associated with graft dysfunction. The use of antiplatelet agents in the included studies was associated with reduced lung injury and improved lung function on EVLP or during lung transplantation.